The late effects of childhood cancer therapy.
In this article the difficulties that face survivors of childhood cancer therapy are presented, and the late effects of such therapy, separated into nonmalignant and malignant late effects, are discussed according to organ system. Recommendations for monitoring the late effects are set forth. A table listing radiation-therapy site and chemotherapeutic agents and selected late effects that result from their use is provided. Finally, a brief recommendation regarding the establishment of a late-effects clinic is also presented.
Dickerman
Joseph D
JD
University of Vermont College of Medicine, Department of Pediatrics, 89 Beaumont Ave, Given D201, Burlington, VT 05405-0068, USA. joseph.dickerman@uvm.edu
D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002318:Cardiovascular Diseases / Q000209:etiology; D002648:Child; D002675:Child, Preschool; D002658:Developmental Disabilities / Q000209:etiology; D004066:Digestive System Diseases / Q000209:etiology; D004700:Endocrine System Diseases / Q000209:etiology; D005260:Female; D052776:Female Urogenital Diseases / Q000209:etiology; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008171:Lung Diseases / Q000209:etiology; D008297:Male; D052801:Male Urogenital Diseases / Q000209:etiology; D009140:Musculoskeletal Diseases / Q000209:etiology; D009369:Neoplasms / Q000453:epidemiology / Q000628:therapy*; D016609:Neoplasms, Second Primary / Q000453:epidemiology; D009422:Nervous System Diseases / Q000209:etiology; D011878:Radiotherapy / Q000009:adverse effects*; D012307:Risk Factors; D017741:Survivors
D000970:Antineoplastic Agents